Not since the commercialization of polymerase chain reaction tests has molecular diagnostics been presented with such a promising technology as next-generation sequencing (NGS), according to healthcare market research firm Kalorama Information. NGS’s blue-chip status was discussed in the recently published The Worldwide Market for In Vitro Diagnostics, 9th Edition.
A new blood test reliably predicts whether a person is likely to develop Alzheimer’s Disease (AD) up to 10 years before the disease is diagnosed, according to a multi-site study recently published in the Alzheimer’s Association journal Alzheimer’s & Dementia.
A novel test used to assess risk for acute kidney injury (AKI) could help physicians significantly improve management of intensive care unit (ICU) patients at risk for AKI, who annually account for 5 million admissions. Inadequacies in assessment and management of AKI have been cited as contributing to an increased number of deaths and excess healthcare costs.[2-3]
BioTime, Inc.’s Subsidiary OncoCyte Corporation and Abcodia to Collaborate on Breast Cancer Diagnostic Development
OncoCyte Corporation, a subsidiary of BioTime, Inc.(NYSE MKT: BTX), and Abcodia Ltd., a UK-based company focusing on the early detection of cancer, recently announced their collaboration focused on the development of OncoCyte’s blood-based PanC-Dx™ test for early detection of breast cancer. PanC-Dx™ is a class of non-invasive cancer diagnostics based on OncoCyte’s proprietary set of cancer markers, which were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. OncoCyte is currently sponsoring four clinical studies of PanC-Dx™ in bladder, breast, and lung cancer.
Improved Survival of Ovarian Cancer Patients Receiving Treatment Guided by Comprehensive Tumour Profiling
Data from an ovarian cancer registry presented at the European Society for Gynaecological Oncology (ESGO) annual meeting reinforce comprehensive tumour profiling as a ‘game changer’ for oncologists.